Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week High - Time to Buy?

Key Points

• 52-week high: Bicara Therapeutics hit a new 52-week high of $22.26 on Monday and carries a consensus "Moderate Buy" rating with an average target of $28 and analyst targets as high as $30.
• The company reported Q1 EPS of ($0.68), beating estimates by $0.04, but remains unprofitable with analysts forecasting -2.59 EPS for the year and a negative P/E of -8.75.
• Insider selling: Insiders sold 137,969 shares (~$2.59M) in the last quarter, including recent sales by the CFO and CEO, which some investors may view as a warning sign.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $22.26 and last traded at $22.14, with a volume of 429576 shares trading hands. The stock had previously closed at $21.12.

Analyst Ratings Changes

Several brokerages have commented on BCAX. UBS Group restated a "buy" rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. The Goldman Sachs Group raised their price target on shares of Bicara Therapeutics from $14.00 to $16.00 and gave the company a "neutral" rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised their price objective on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 31st. Citigroup began coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set an "outperform" rating on the stock. Finally, Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.00.

Bicara Therapeutics Price Performance

The stock's fifty day moving average is $17.92 and its two-hundred day moving average is $17.25. The stock has a market capitalization of $1.45 billion, a P/E ratio of -8.75 and a beta of -1.23.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.04. Analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, CFO Ivan Hyep sold 9,200 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $18.52, for a total value of $170,384.00. Following the completion of the sale, the chief financial officer owned 145,355 shares in the company, valued at $2,691,974.60. This represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Claire Mazumdar sold 1,596 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20. Following the completion of the sale, the chief executive officer owned 339,392 shares of the company's stock, valued at approximately $6,431,478.40. The trade was a 0.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 137,969 shares of company stock worth $2,586,198 in the last quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the 4th quarter valued at $45,000. Legal & General Group Plc raised its holdings in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock valued at $62,000 after purchasing an additional 3,595 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock valued at $44,000 after purchasing an additional 3,866 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after purchasing an additional 4,585 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.